Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight
Authors
Keywords
-
Journal
CIRCULATION
Volume 139, Issue 20, Pages 2292-2300
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-02-18
DOI
10.1161/circulationaha.118.037955
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry
- (2018) Giuseppe Boriani et al. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
- Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis
- (2017) Carl J. Lavie et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis
- (2017) K. Boonyawat et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Is There an Obesity Paradox for Outcomes in Atrial Fibrillation?
- (2017) Marco Proietti et al. STROKE
- The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
- (2016) Roopinder K. Sandhu et al. EUROPEAN HEART JOURNAL
- Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
- (2016) K. Martin et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine
- (2016) John H. Alexander et al. JAMA Cardiology
- Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials
- (2015) Matteo Nicola Dario Di Minno et al. ANNALS OF MEDICINE
- Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
- (2015) Charles E. Frost et al. CLINICAL PHARMACOKINETICS
- Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
- (2015) Ming Chang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
- (2014) Cynthia L. Ogden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
- (2013) Vijay V. Upreti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Apixaban for the Treatment of Acute Venous Thromboembolism
- (2013) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
- (2010) Renato D. Lopes et al. AMERICAN HEART JOURNAL
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started